Pfizer's Once-a-Month Obesity Shot Just Crashed the Biggest Party in Pharma

The more interesting story came from VESPER-3, which tested Pfizer's real pitch to the market. Patients started on weekly injections, then switched to monthly maintenance shots. At 28 weeks, the best-performing group hit 12.3% placebo-adjusted weight loss on a monthly dose of 4.8 mg. That means after subtracting whatever weight the sugar-pill group lost, the drug still delivered a double-digit reduction.

Every dosing group in VESPER-3 beat placebo with statistical significance (P<0.001), and the weight-loss curves were still heading downward at week 28. Pfizer says the trial is continuing through week 64, so the final numbers could climb higher.

The Tolerability Angle Is Quietly Important

GLP-1 drugs work well, but they're infamous for making patients nauseous. It's the number-one reason people quit taking them. Think of it like a gym membership that makes you throw up every time you walk through the door; results are great, but compliance is a problem.

Berobenatide's tolerability data look notably clean. Across the VESPER studies, GI side effects (nausea, vomiting, diarrhea) were mostly mild or moderate. In VESPER-3, no more than one case of severe nausea or vomiting appeared in any dose group, and there was zero severe diarrhea. Pfizer achieved this even with rapid dose escalation and no option for patients to step down to a lower dose.

That's a meaningful differentiator if it holds up in larger Phase 3 trials. Each monthly injection is just 0.5 mL, a tiny volume, which also helps on the convenience front.

A Crowded Dance Floor in New Orleans

Pfizer wasn't the only company showing off at ADA 2026. The obesity presentations read like a who's-who of big pharma:

• Eli Lilly brought Phase 3 data for retatrutide, its triple-agonist (GLP-1/GIP/glucagon) that targets three metabolic pathways at once, plus fresh results for the oral GLP-1 orforglipron.
• Novo Nordisk presented Phase 3 results for CagriSema, its combination of semaglutide and an amylin analog.
• Boehringer Ingelheim unveiled Phase 3 data for survodutide, a dual glucagon/GLP-1 agonist.
• Roche showed Phase 2 obesity data from CT-388, its GLP-1/GIP program acquired from Carmot.

Some of these next-generation agents are targeting 20%+ weight loss in pivotal trials. Against that backdrop, berobenatide's 12.3% placebo-adjusted number at 28 weeks is competitive but not category-leading.

Wall Street Said "Nice, But Show Me More"

Pfizer shares dropped about 3–3.5% after the data presentation, which tells you everything about investor expectations. The numbers were good. They just weren't good enough to change the narrative overnight.

Daniel Barasa of Gabelli Funds captured the mood perfectly, calling the weight loss "good, but not category-defining." That phrase has become the unofficial Wall Street consensus on berobenatide: it validates the science, it de-risks the Phase 3 program, but it doesn't vault Pfizer into the same conversation as Lilly and Novo.

Analysts see Pfizer as a "cheap obesity option" for investors. The stock trades at a low valuation multiple because of patent cliffs and lingering COVID revenue drag. If berobenatide delivers in Phase 3 and launches around 2028, it could meaningfully move the needle. But that's a lot of "ifs" for a company entering a market where incumbents already have years of prescriber familiarity and massive manufacturing scale.

The $100 Billion Question

The global obesity drug market is growing rapidly. Goldman Sachs projects it'll hit roughly $95 billion by 2030. Morgan Stanley thinks it could peak at $150 billion by 2035. Even if those numbers get trimmed by pricing pressure and competition, the market is enormous.

Pfizer's bet isn't that berobenatide will be the best obesity drug on the planet. It's that in a market this large, there's room for a monthly, well-tolerated, primary-care-friendly option alongside the weekly blockbusters. The company plans to launch 10 Phase 3 trials for berobenatide in 2026, covering not just weight management but related conditions like knee osteoarthritis and obstructive sleep apnea.

That's an aggressive playbook. Pfizer is essentially carpet-bombing the clinical landscape, hoping that breadth of evidence and convenience of dosing can offset an efficacy gap against the leaders.

The Bottom Line

Pfizer showed up late to the obesity party, got punched in the face twice by its own pipeline failures, and rebuilt its entire strategy around an acquired asset. The berobenatide data from ADA 2026 won't make anyone forget Zepbound or Wegovy. But a once-monthly shot with clean tolerability and double-digit weight loss? In a $100 billion market, that's not nothing.

The real test comes in Phase 3. Pfizer needs to prove that 28-week results hold (or improve) over a full year, that the tolerability advantage survives in thousands of patients, and that monthly dosing actually changes prescribing behavior. Until then, berobenatide remains what Wall Street loves to call it: an option on future growth.

An expensive, intriguing, still-unproven option.

Lilly's New Weight-Loss Drug Makes Ozempic Look Like a Warm-Up

Eli Lilly's triple-agonist retatrutide just posted 28% average weight loss in a Phase 3 trial, blowing past every GLP-1 drug on the market. The post-Ozempic era officially has a frontrunner.